Inferra AIResearch Tools

Inferra AI / Company / ALNY

Alnylam Pharmaceuticals

ALNY · Health Care

Last earnings Oct 29, 2026

Key results

Total Net Product revenuequarter

$851 Million

Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total TTR revenuequarter

$724 Million

Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) Continued Broad Access and Balanced Utilization of

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Revenuequarter

135%

Third Quarter 2025 and Recent Significant Business Highlights Total TTR AMVUTTRA (vutrisiran) ONPATTRO (patisiran) Achieved global net product revenues for AMVUTTRA and ONPATTRO for the third quarter of $685 million and $39 million, respectively, representing $724 million in total TTR net product revenues and 135% total TTR growth compared to Q3 2024.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total Rare GIVLAARI (givosiran) OXLUMO (lumasiran) Achieved global net product revenues for GIVLAARI and OXLUMO for the third quarter of $74 million and $53 million, respectively, representing $127 million in total Rare net product revenue and 14% total Rare growth compared to Q3 2024.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total Net Product Revenues Total net product revenues increased 103% and 99% at actual currency and CER, respectively, during the three months ended September 30, 2025, as compared to the same period in 2024, primarily due to growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR amyloidosis with cardiomyopathy in the U.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

revenues increased 103% and 99% at actual currency and CER, respectively, during the three months ended September 30, 2025, as compared to the same period in 2024, primarily due to growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR amyloidosis with cardiomyopathy in the U.S.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Net Revenues from Collaborations Net revenues from collaborations increased during the three months ended September 30, 2025, as compared to the same period in 2024, primarily driven by recognition of $300 million of milestone revenue under our collaboration with Roche in September 2025 associated with the dosing of the first patient in the ZENITH Phase 3 clinical trial of zilebesiran.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

2024 at currency exchange rates as of September 30, 2025 1 61% to 70% 79% to 85% Net product revenues growth vs.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Research and developmentquarter

$358,814 thousand

Research and development 358,814 270,926 947,557 826,063

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Selling, general, and administrativequarter

$322,076 thousand

Selling, general and administrative 322,076 220,993 885,339 680,187

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Net incomequarter

$251,084 thousand

Net income (loss) $ 251,084 $ (111,570) $ 127,328 $ (194,394)

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

AI analysis

Q3 2025 · reported Oct 30, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Net income · Q3 2025
$251,084 thousand
EX-99 · Oct 30, 2025
Total Net Product revenue · Q3 2025
$851M
+26.6% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Total TTR revenue · Q3 2025
$724M
+33.1% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Research and development · Q3 2025
$358,814 thousand
+10.9% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025

The quarter in charts

Segment mix

Business-unit revenue, as stated

0300600900$851MTotal Net Product$724MTotal TTR

Segment revenue figures as stated in the event record.

Headline figures

MetricQ3 2025Prior qtrYear ago
Total Net Product revenue$851 Million$672 Million—
Total TTR revenue$724 Million$544 Million—
Revenue135%64%—
Research and development$358,814 thousand$323,621 thousand—
Selling, general, and administrative$322,076 thousand$323,314 thousand—
Net income$251,084 thousand——

EX-99 · Oct 30, 2025

Guidance · company-stated

Direction: Raised

Revenue$2.95 billion

“Based on the ATTR-CM launch trajectory, we are again raising our guidance and expect total net product revenues of $2.95 billion to $3.05 billion for 2025.”

Revenue

“2025 Financial Guidance Full-year 2025 financial guidance is updated and consists of the following Item Prior FY 2025 Guidance Updated FY 2025 Guidance Total TTR net product revenues (PN CM) (AMVUTTRA, ONPATTRO) 1 $2,175 million - $2,275 million $2,475 million - $2,525 million Total Rare net product revenues (GIVLAARI, OXLUMO) $475 million - $525 million Reiterate FY guidance Total net product revenues $2,650 million - $2,800 million $2,950 million - $3,050 million Net product revenues growth vs.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Issued $661 million in 0.00% convertible senior notes due 2028, with proceeds primarily used to partially repurchase Alnylam's 1.00% convertible senior notes due 2027.

Entered into a $500 million revolving credit facility providing flexible access to funds for general corporate purposes.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Alnylam s impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to patients around the world, said Yvonne

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “Based on the ATTR-CM launch trajectory, we are again raising our guidance and expect total net product revenues of $2.95 billion to $3.05 billion for 2025.”

Revenue: “2025 Financial Guidance Full-year 2025 financial guidance is updated and consists of the following Item Prior FY 2025 Guidance Updated FY 2025 Guidance Total TTR net product revenues (PN CM) (AMVUTTRA, ONPATTRO) 1 $2,175 million - $2,275 million $2,475 million - $2,525 million Total Rare net product revenues (GIVLAARI, OXLUMO) $475 million - $525 million Reiterate FY guidance Total net product revenues $2,650 million - $2,800 million $2,950 million - $3,050 million Net product revenues growth vs.”

Revenue — Raised (“raising”)
“Based on the ATTR-CM launch trajectory, we are again raising our guidance and expect total net product revenues of $2.95 billion to $3.05 billion for 2025.”

Revenue — Reiterated (“Reiterate”)
“2025 Financial Guidance Full-year 2025 financial guidance is updated and consists of the following Item Prior FY 2025 Guidance Updated FY 2025 Guidance Total TTR net product revenues (PN CM) (AMVUTTRA, ONPATTRO) 1 $2,175 million - $2,275 million $2,475 million - $2,525 million Total Rare net product revenues (GIVLAARI, OXLUMO) $475 million - $525 million Reiterate FY guidance Total net product revenues $2,650 million - $2,800 million $2,950 million - $3,050 million Net product revenues growth vs.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Issued $661 million in 0.00% convertible senior notes due 2028, with proceeds primarily used to partially repurchase Alnylam's 1.00% convertible senior notes due 2027.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Entered into a $500 million revolving credit facility providing flexible access to funds for general corporate purposes.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total other expense, net Total other expense, net for the three months ended September 30, 2025 of $129 million included a charge associated with the change in fair value of the development derivative liability of $65 million primarily driven by updates to estimated royalties due to Blackstone on net sales of AMVUTTRA and a loss related to convertible debt of $39 million, representing an inducement expense on the partial repurchase of the 1.00% convertible senior notes due 2027.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Financial position Cash, cash equivalents and marketable securities were $2.7 billion as of September 30, 2025, as compared to $2.9 billion as of June 30, 2025, with the decrease primarily driven by the partial repurchase of the 1.00% convertible senior notes due 2027, offset in part by net proceeds from the issuance of 0.00% convertible senior notes due 2028 and net cash inflows from operating activities.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Net cash provided by operating activities for the three months ended September 30, 2025 included $19 million of payments associated with the liability related to the sale of future Leqvio royalties recorded to interest expense, as well as $3 million of accrued interest paid upon the partial repurchase of the 1.00% convertible senior notes due 2027.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Partially offset by $646 million of net proceeds from issuance of 0.00% convertible senior notes due 2028, and $78 million of proceeds from exercise of employee stock options.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Strategy & priorities

Alnylam is executing on its Alnylam P 5 x25 strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic collaborations with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic collaborators.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

, or, collectively, Roche, pursuant to which we and Roche established a worldwide, strategic collaboration for the joint development of zilebesiran.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

Overview In 2019, we entered into a global, strategic collaboration with Regeneron Pharmaceuticals, Inc.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

Risks & headwinds

LEGAL PROCEEDINGS 46 ITEM 1A.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

Given these uncertainties, you should not place undue reliance on these forward-looking statements.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

Any such third-party data, as well as our internal estimates and research, are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in Part II, Item 1A, Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Alnylam Pharmaceuticals — 10-Q Quarterly report10-QOct 29, 2026

What changed vs prior quarter

Total Net Product revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Total TTR revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Alnylam Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Documents

Earnings deck slides

4 decks with slide view

Slide history — recurring slides by stated title

Slides are matched across this company’s decks by their stated title only; a title listed here appeared in more than one held deck.

Industry Leading Pipeline of RNAi Therapeutics — Oct 29, 2026 · slide 7 · Oct 29, 2026 · slide 8 · Oct 29, 2026 · slide 25

- Loking Statements — Oct 29, 2026 · slide 2 · Oct 29, 2026 · slide 4

Agenda — Oct 29, 2026 · slide 3 · Oct 29, 2026 · slide 2

Pionering a Generational Clas of RNAi Medicines — Oct 29, 2026 · slide 5 · Oct 29, 2026 · slide 6

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

65 documents

Earnings releases

23 documents

Presentations

4 documents

Transcripts

0 documents

No transcripts for Alnylam Pharmaceuticals are held in this edition of the library.

Mentioned by

4 companies

Other tracked companies whose held documents mention Alnylam Pharmaceuticals by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.